Join us for an exclusive Deep Dive event focused on Advancing Antibody-Drug Conjugates on Wednesday 30 April 2025 at BioArk, in Monthey.
BioArk and BioAlps invite you to explore the fast-evolving world of Antibody-Drug Conjugates (ADCs) and bioconjugates.
ADCs are revolutionizing targeted therapies, and are opening new possibilities for cancer treatment and beyond.
This half -day session brings together key opinion leaders (KOLs) from Debiopharm, Lonza, Ninsun Biotech, and HES-SO Valais/Wallis to explore the latest advancements in ADC technology, from innovative linker chemistries to scalable biomanufacturing. Experts will discuss challenges in ADC development, regulatory perspectives, and strategies to accelerate clinical translation. The event fosters interdisciplinary dialogue between academia and industry, aiming to drive innovation and therapeutic breakthroughs.
Whether you’re a researcher, entrepreneur, or investor, this event offers valuable insights and connections.
Don’t miss this unique opportunity to network with industry leaders, to dive deep into one of biotech’s most promising domains.
Programme
1.00 pm | Welcome of Participants
1.30 pm | Welcome Address
- Sandra Ansanay-Alex, Sr. Communication & Event Manager, BioAlps
- Massimo Nobile, Site Manager, BioArk Monthey
1.45 pm | Presentations
- Prof. Origene Nyanguile, Professor, HES-SO Valais-Wallis (Institut of Life Sciences)
- Dr. Leo Marx, Medicinal Chemist & Bioconjugation Manager, Debiopharm
- Dr. François Ricard, Global Head of R&D small molecules and bioconjugates, Lonza
- Dr. Boutaïna Chandouri-Faize, CTO, Ninsun Biotech
3.05 pm | Speakers on the grill
3.35 pm | Closing Remarks
3.45 pm | Networking
📆 30 April 2025
📍 BioArk Monthey – Rte de l’Ile-au-Bois 1A, 1870 Monthey
🗣 Language | English
⚠️ Registration is free but mandatory. Limited seats available.
